Chapel Hill, NC, United States of America

Muralikrishna Duvvuri

This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Cavion, Inc., Ventirx Pharmaceuticals, Inc., Embera Neurotherapeutics, Inc.. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Muralikrishna Duvvuri. Retrieved from https://idiyas.com/inventor/muralikrishna-duvvuri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 3)

% Patents Active = 60.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 9(Granted Patents)

Location History:

Durham, NC (US) (2012 - 2015)
Chapel Hill, NC (US) (2021 - 2022)

Company Filing History:

Ventirx Pharmaceuticals, Inc.

patents

1 out of 3

Embera Neurotherapeutics, Inc.

patents

Years Active: 2012-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383539 - Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide (2025-08-12),

2. 11311522 - Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide (2022-04-26),

3. 11179377 - Pharmaceutical compositions and uses thereof (2021-11-23),

4. 9216192 - Toll-like receptor agonist formulations and their use (2015-12-22),

5. 8242106 - Toll-like receptor agonist formulations and their use (2012-08-14),

Title: **Innovator Spotlight: Muralikrishna Duvvuri**

Introduction

Muralikrishna Duvvuri is an accomplished inventor based in Durham, NC, specializing in biomedical innovations with significant implications for cancer treatment. With a total of two patents to his name, he has contributed valuable advancements in the field of pharmacology, particularly through his work on Toll-like receptor agonist formulations.

Latest Patents

Duvvuri's most recent patents focus on stable formulations of Toll-like receptor (TLR) agonists, specifically TLR7 and TLR8, which are integral in the fight against cancer, particularly solid tumors and lymphomas. These formulations are designed to stabilize TLR agonists at concentrations of up to 50 mg/ml, incorporating cyclodextrins to enhance stability and efficacy. His innovative approaches aim to improve therapeutic options for patients battling cancer by harnessing the body’s immune response.

Career Highlights

Currently, Duvvuri is associated with Ventirx Pharmaceuticals, Inc., where his research endeavors focus on advancing TLR agonist technologies. His commitment to innovation in pharmaceutical sciences is evident in his patent work, which underscores the importance of developing effective cancer therapies.

Collaborations

Throughout his career, Duvvuri has collaborated with esteemed colleagues, including J Jeffry Howbert and Robert Hershberg. These partnerships reflect a collective effort toward pioneering advancements in cancer treatment through TLR agonists and similar therapies.

Conclusion

Muralikrishna Duvvuri exemplifies the spirit of innovation, demonstrating how dedicated research and collaboration can lead to significant advancements in the medical field. His contributions through his patents not only spotlight his expertise but also highlight the potential for improved cancer treatments that stem from the innovative power of science.

Profile summary based on public USPTO records.